-CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Insti...
Cytiva has deepened its partnership with Culture Biosciences, introducing the Stratyx 250 process development bioreactor. Speaking to BioPharma Boa...
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company prov...
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...
Culture Biosciences, an expert in cloud-connected bioreactor technology, and Cytiva, a Danaher company and a leader in the life sciences industry, ...
SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and ...
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery CAS, a division of the American Chemical Soci...
BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...
AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partn...
Bio Usawa, a pioneering private biotechnology company committed to developing and manufacturing affordable, high‑quality monoclonal antibody therapies ...
POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovatio...
Everlab, the AI-powered health platform reimagining preventive care, announced a US$10 million (AU$15 million) seed round led by global growth equity fir...
Moderna provided an update on its two planned research and manufacturing facilities at Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefectu...
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is...
© 2025 Biopharma Boardroom. All Rights Reserved.
